USD 23.53 billion
Report ID:
SQMIG35I2293 |
Region:
Global |
Published Date: October, 2024
Pages:
157
|Tables:
94
|Figures:
76
Global Multiple Myeloma Market size was valued at USD 21.98 billion in 2022 and is poised to grow from USD 25.30 billion in 2023 to USD 77.93 billion by 2031, growing at a CAGR of 15.1% in the forecast period (2024-2031).
Surging prevalence of multiple myeloma and growing investments in oncology research are projected to primarily augment market development. Advancements in cancer treatment therapies and the growing use of CAR-T cell therapies, monoclonal antibodies, and immune checkpoint inhibitors for the treatment of multiple myeloma are also slated to benefit market players in the future. High investments in the R&D of multiple myeloma treatment and diagnostics coupled with the rising use of personalized medicine are also expected to create new opportunities for multiple myeloma companies going forward. Launch of new initiatives to promote awareness regarding multiple myeloma and increasing efforts to promote early diagnosis of multiple myeloma are also slated to expand the business scope for multiple myeloma providers. On the contrary, high costs of treatment, risk of adverse effects of treatment, lack of awareness, and development of treatment resistance are some key constraints that are estimated to impede multiple myeloma market outlook in the long run.
US Multiple Myeloma Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 23.53 billion
Largest Segment
Hospital Pharmacies
Fastest Growth
Hospital Pharmacies
Growth Rate
6.5% CAGR
To get more reports on the above market click here to Buy The Report
Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs, Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Multiple Myeloma Market Analysis by Therapy
Chemotherapy is projected to account for a significant multiple myeloma market share over the coming years. High preference and use of chemotherapy for the treatment of a wide variety of oncology indications and proven efficacy of the same are helping this segment maintain its dominant stance. Most healthcare establishments and healthcare professionals use chemotherapy as a standard treatment for multiple myeloma as it focuses on targeting the rapidly dividing cancer cells in the body. The presence of multiple studies exploring the use of chemotherapy for treatment of various cancers and high availability of chemotherapy alternatives for multiple myeloma are also contributing to the high market share.
On the other hand, the use of radiation therapy for the treatment of multiple myeloma is expected to increase at a rapid pace in the future. High R&D investments to explore the efficacy of radiotherapy for multiple myeloma treatment, and advancements in radiation technologies, are also expected to create new opportunities for multiple myeloma treatment providers going forward. Intensity-modulated radiation therapy, stereotactic body radiation therapy, and proton therapy are forecasted to be highly popular in this segment as they enhance the efficiency of radiation delivery for cancer indication treatment.
Multiple Myeloma Market Analysis by Distribution Channel
Hospitals are forecasted to account for a prominent chunk of the global multiple myeloma market share in the future. Growing use of prescribed multiple myeloma treatment drugs and increasing rate of hospitalization in multiple myeloma cases are expected to help this segment emerge as a dominant one. Proper adherence to medication and treatment in hospital settings is also a key factor allowing hospitals to hold sway over other distribution channels. The complex nature of multiple myeloma treatment also makes it necessary for proper adherence to multiple medications and requires a multidisciplinary approach to improve chances of successful treatment, thereby making hospitals the best channel for multiple myeloma treatment delivery.
Meanwhile, the online pharmacies segment is projected to exhibit an impressive growth across the study period. Increasing preference of patients to shop for medications and drugs from the convenience of their homes is expected to help this segment generate new opportunities for multiple myeloma companies going forward. Rising availability of new online pharmacies providing multiple myeloma treatment drugs and increasing internet penetration around the world are also estimated to boost revenue generation for multiple myeloma companies focusing on this segment. Rise of digital health and increasing digitization of the healthcare industry are also expected to offer new business scope for multiple myeloma treatment providers targeting online pharmacies going forward.
To get detailed analysis on other segments, Request For Free Sample Report
North America is estimated to secure the top spot when it comes to the multiple myeloma market. Surging incidence of multiple myeloma, high investments in oncology R&D, and growing geriatric population are some key factors that are estimated to aid the dominance of North America in the future. The United States is projected to spearhead the demand for multiple myeloma treatment followed by Canada going forward. High patient awareness regarding symptoms of multiple myeloma, availability of novel treatment therapies and drugs, and shorter approval times for novel therapies are also estimated to aid the dominance of North America in the long run.
Growing awareness regarding symptoms of multiple myeloma is helping Asia Pacific emerge as the fastest-growing market for multiple myeloma companies in the world. High investments in healthcare infrastructure development, launch of new awareness initiatives, and increasing healthcare expenditure are some major factors helping generate new opportunities for market players. As per this multiple myeloma market forecast, China, Japan, and India are expected to be highly opportune markets for multiple myeloma companies owing to a major surge in senescent population in these countries. Increasing availability of novel multiple myeloma treatment therapies and drugs coupled with high emphasis on early diagnosis are also estimated to benefit the multiple myeloma industry in this region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Multiple Myeloma Market Driver
Growing Geriatric Population
High Investments in Research and Development
Restraints
Side Effects of Treatment
Lack of Awareness Regarding Symptoms
Request Free Customization of this report to help us to meet your business objectives.
Multiple myeloma treatment providers should focus on increasing awareness regarding the condition to maximize their business scope going forward. Investing in the research and development of novel multiple myeloma treatments with minimal side effects is also expected to be a key strategy for all market players. Collaborations, mergers, product approvals, new product launches, and acquisitions are slated to be key strategies used by multiple myeloma companies to expand their market presence.
Multiple Myeloma Market Top Players Company Profiles
Multiple Myeloma Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, growing incidence of multiple myeloma and rising geriatric population are expected to be key factors driving the global multiple myeloma market development. On the contrary, risk of side effects and lack of awareness regarding symptoms are slated to be key restraints for multiple myeloma companies in the future. North America is estimated to be the top market for multiple myeloma providers owing to the presence of a developed healthcare infrastructure and high investments in oncology R&D. Use of minimally invasive approach and personalized medicine approach are projected to create new opportunities for multiple myeloma treatment providers in the long run.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 21.98 billion |
Market size value in 2031 | USD 77.93 billion |
Growth Rate | 15.1% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Multiple Myeloma Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Multiple Myeloma Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Multiple Myeloma Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Multiple Myeloma Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35I2293
sales@skyquestt.com
USA +1 351-333-4748